Ventipulmin antagonises the effects of prostaglandin F2-alpha and oxytocin.

Ventipulmin is antagonised by beta-adrenergic blocking agents.

If used during pregnancy, treatment must be discontinued at the expected time of delivery since uterine contractions may be abolished under its influence.

Animals must not be slaughtered for human consumption during treatment. Horses may be slaughtered for human consumption only after 28 days from the last treatment.

Do not use in cases of known sensitivity to clenbuterol. Sweating and transient mild muscle tremor may occur after intravenous administration in some horses. It is suggested that a may be responsible for this, causing transient peripheral vasodilation.

Vasodilation is a feature of all beta-adrenergic drugs to a greater or lesser degree and may be minimised by administering Ventipulmin slowly.

When using do not eat, drink or smoke. After use wash any contaminated skin immediately with soap and clean water.

This product contains clenbuterol, a beta-agonist. Accidental self-injection may produce tachycardia and tremor. These effects may be reversed by the use of a non-selective beta-blocker. If accidental self-injection occurs seek medical advice immediately avoiding driving if possible. Unused product and containers should be disposed of in accordance with national requirements.

For animal treatment only. Keep out of the reach and sight of children.